Uncategorized
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update. “Quarterly revenue from our eyecare and wound care segment increased 10% versus the prior year, driven by higher Avenova sales through our physician dispensed and OTC channels, and by higher sales of our branded wound care products,” said Justin Hall, CEO of NovaBay. “Last year we expanded our loyal